Sai Life Sciences is strategically positioning itself to benefit from the global shift in pharmaceutical supply chains beyond China, as rising demand for outsourced research and manufacturing creates opportunities for Indian contract research, development and manufacturing organisations. According to reports from NDTV Profit, the company's integrated CRDMO model, long-term relationships with global pharmaceutical companies, growing late-stage drug pipeline and investments in manufacturing capacity are central to its growth strategy. The company's expansion into peptides and oral solid formulations could add further opportunities as drug pipelines become more complex. Sai Life Sciences is also expanding beyond traditional small molecules into specialised therapeutic modalities, developing a peptide platform that will cover the development cycle from early discovery to commercial manufacturing, with a greenfield peptide API manufacturing facility scheduled to begin operations in 2028.
Sai Life Sciences reported 12% year-on-year revenue growth in Q1FY27 to ₹554 crore, with the CRO business leading growth at 24% while CDMO revenue rose 6%. As reported by NDTV Profit, profit increased faster than revenue with EBITDA rising 18% to ₹148 crore and the EBITDA margin expanding by 200 basis points to 27%. Net profit increased 22% to ₹73 crore. The company expects revenue to grow at a 15% to 20% CAGR over the next three to five years, with EBITDA margins of 28% to 30%. Sai Life Sciences expects to finalise and sign contract terms with a large pharmaceutical client before the end of Q2FY27, with revenue recognition beginning from Q3FY27, supporting expectations of significantly stronger revenue and earnings in H2FY27.
Sai Life Sciences shares have risen 76% in 2026, significantly outperforming the Nifty Pharma Index which gained 26% during the same period. According to NDTV Profit, the Indian CRDMO market is expected to grow at a compound annual growth rate of 15% to 16% through 2035. At ₹1,585 per share, Sai Life Sciences trades at an EV/EBITDA multiple of 48.3x, which is below Laurus Labs at 52x and Divi's at 55x. The company's return metrics have improved with Return on Equity increasing to 14% in FY26 from 8% in FY25, while Return on Capital Employed rose to 18.2% from 12.2%.
Sai Life Sciences plans to invest ₹1,100-1,300 crore in capital expenditure in FY27, with 75% allocated towards capacity expansion. As reported by NDTV Profit, the company is adding 450 kilolitres of capacity across production blocks, taking total capacity to 1,150 kilolitres in FY27. The first 225-kilolitre manufacturing block is expected to become operational in the second half of FY27. The company also plans to launch oral solid formulation capabilities for initial clinical supply by Q4FY27, allowing it to offer an API-plus-drug-product solution from a single location. Capacity utilisation stood at 65% in Q1FY27, leaving 35% of capacity available for additional production volumes as new manufacturing blocks become operational.
Sai Life Sciences currently has 33 to 34 active commercial molecules and 14 late-phase molecules. According to NDTV Profit, the company's pipeline covers several therapeutic areas with oncology accounting for 25% of FY26 revenue, followed by brain and nervous system at 16%, infectious diseases and metabolic disorders at 15% each, and cardiovascular at 8%. The company operates across contract research and contract development and manufacturing, with CDMO accounting for 60% of revenue in Q1FY27. Sai Life Sciences works with 19 of the top 25 global pharmaceutical companies and more than 90% of its revenue comes from returning, long-term clients with average relationships exceeding 11 years. The FTE model is helping the company move more molecules into its CDMO pipeline, with five of the six late-phase molecules added over the past 15 months originating from large pharmaceutical FTE engagements.
